Trends in antimalarial drug deployment in sub-Saharan Africa.
about
Unit-dose packaged drugs for treating malariaArtemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trialCost-Effectiveness Analysis of Test-Based versus Presumptive Treatment of Uncomplicated Malaria in Children under Five Years in an Area of High Transmission in Central GhanaNovel Plasmodium vivax dhfr alleles from the Indonesian Archipelago and Papua New Guinea: association with pyrimethamine resistance determined by a Saccharomyces cerevisiae expression system.Artemisinin combination therapies for treatment of uncomplicated malaria in Uganda.Developing geostatistical space-time models to predict outpatient treatment burdens from incomplete national dataWillingness to pay for rapid diagnostic tests for the diagnosis and treatment of malaria in southeast Nigeria: ex post and ex ante.Factors associated with non-adherence to Artemisinin-based combination therapy (ACT) to malaria in a rural population from holoendemic region of western Kenya.Factors determining anti-malarial drug use in a peri-urban population from malaria holoendemic region of western KenyaAre rapid diagnostic tests more accurate in diagnosis of plasmodium falciparum malaria compared to microscopy at rural health centres?Putting the genie back in the bottle? Availability and presentation of oral artemisinin compounds at retail pharmacies in urban Dar-es-Salaam.An interactive model for the assessment of the economic costs and benefits of different rapid diagnostic tests for malariaPerceptions of malaria and acceptance of rapid diagnostic tests and related treatment practises among community members and health care providers in Greater Garissa, North Eastern Province, Kenya.Consumers stated and revealed preferences for community health workers and other strategies for the provision of timely and appropriate treatment of malaria in southeast Nigeria.Prevention of congenital transmission of malaria in sub-saharan african countries: challenges and implications for health system strengthening.Implementation of artemether-lumefantrine treatment policy for malaria at health facilities in Tanzania.Association between HRP-2/pLDH rapid diagnostic test band positivity and malaria-related anemia at a peripheral health facility in Western Uganda.Levels of adherence to coartem© in the routine treatment of uncomplicated malaria in children aged below five years, in kenya.A comparative, randomized clinical trial of artemisinin/naphtoquine twice daily one day versus artemether/lumefantrine six doses regimen in children and adults with uncomplicated falciparum malaria in Côte d'Ivoire.Malaria treatment perceptions, practices and influences on provider behaviour: comparing hospitals and non-hospitals in south-east Nigeria.Chloroquine Resistant Plasmodium falciparum in Nigeria: Relationship between pfcrt and pfmdr1 Polymorphisms, In-Vitro Resistance and Treatment Outcome.Cost-effectiveness analysis of rapid diagnostic test, microscopy and syndromic approach in the diagnosis of malaria in Nigeria: implications for scaling-up deployment of ACT.Introducing rapid tests for malaria into the retail sector: what are the unintended consequences?Appropriating "malaria": local responses to malaria treatment and prevention in Abidjan, Cote d'Ivoire.Where do people from different socio-economic groups receive diagnosis and treatment for presumptive malaria, in south-eastern Nigeria?Malaria over-diagnosis in Cameroon: diagnostic accuracy of Fluorescence and Staining Technologies (FAST) Malaria Stain and LED microscopy versus Giemsa and bright field microscopy validated by polymerase chain reaction.Local terminology for medicines to treat fever in Bougouni District, Mali: implications for the introduction and evaluation of malaria treatment policies.Prevalence of malaria parasitemia among clients seeking treatment for fever or malaria at drug stores in rural Tanzania 2004.Improving the first-line treatment of febrile illnesses in Ghana: willingness to pay for malaria rapid diagnostic tests at licensed chemical shops in the Kintampo area.
P2860
Q24246943-9DB30ACC-D977-4FD7-85AA-9D730BB83E80Q28469217-A2A75C29-7086-4729-B3A4-2CDF34244CFCQ28554436-896CED34-72A6-489E-97EA-2F0CAB39C363Q31143848-28902A1A-C941-449D-B585-6686B2F1ED9DQ33251914-EC23C4FB-E73C-4B5C-ABFD-27B404BE28EAQ33423015-63FB5A33-FDD1-4C30-9D7E-14567EE5B88FQ33645314-CED9336D-9CCE-4977-B82B-863BD7D93885Q34315195-9A9C5E41-E86A-4D52-9D9C-B8D7B5074A3FQ34322243-B0EFD9B9-4A7F-4E45-B7A0-6FD7731B9D43Q34408438-A93B499A-F357-4D2B-8A35-C79003D7F6B4Q34557276-1F6CCC7A-7666-420D-A361-EED20481D072Q34742701-B285EBEC-A9AE-46ED-BA03-22BFF4232EEBQ34990774-DB780FD8-6C60-46E0-A118-D5E262619158Q35222336-656727D7-09AF-4025-85C0-8ACF5C5DDE2CQ35231808-5E9B037D-30F0-4A6E-9950-66171755F3B9Q35727781-43B879D9-26A9-473B-9B69-03A382214F9CQ35881907-05E94B2F-FDCD-4D98-9046-F78A9AA57CA2Q36678922-6C45F71E-94B6-474E-B10A-A185E9ADAAD5Q37271800-072001B6-FC4A-4793-9C11-EB12DD5E9B4CQ37417711-EFC98F4C-40BC-48C6-9DD0-7A6997CA4B5FQ37445582-049905CE-EA83-496C-A6DA-B37CCE28C97BQ37455047-989AA99E-CE45-484D-9173-15376827876DQ37659926-0ACBE3F5-C209-479B-9548-8765AB9FB933Q39031069-9915B8ED-E70A-4B73-8480-9F93997621B1Q39325552-6E113206-0351-4AE7-AAEB-EB5EB632247EQ40062665-59CB2109-E136-49A4-AEBB-13BC73811936Q40468990-D8E795CF-6AC1-42B6-B9E9-73FD51D2D9D9Q40483256-A9E03CE9-F087-4527-BC04-8836D226B60FQ49819700-F2C725BA-C1F8-41F7-9B03-7B332BCD3CB4
P2860
Trends in antimalarial drug deployment in sub-Saharan Africa.
description
2003 nî lūn-bûn
@nan
2003 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Trends in antimalarial drug deployment in sub-Saharan Africa.
@ast
Trends in antimalarial drug deployment in sub-Saharan Africa.
@en
type
label
Trends in antimalarial drug deployment in sub-Saharan Africa.
@ast
Trends in antimalarial drug deployment in sub-Saharan Africa.
@en
prefLabel
Trends in antimalarial drug deployment in sub-Saharan Africa.
@ast
Trends in antimalarial drug deployment in sub-Saharan Africa.
@en
P2093
P356
P1476
Trends in antimalarial drug deployment in sub-Saharan Africa.
@en
P2093
Bloland PB
Williams HA
P304
P356
10.1242/JEB.00637
P577
2003-11-01T00:00:00Z